ABM to allocate PLN 300 mln for implementation of RNA technology in Poland

Prime Minister Mateusz Morawiecki entrusted the Medical Research Agency (ABM) with substantive coordination of matters related to the implementation of the production of vaccines based on mRNA technology in Poland. The measures taken are to prepare for possible future pandemics and to protect Polish patients.

“We are launching government funds at the beginning of the amount of PLN 300 million and in May we will launch and settle our program, wherein several grants of several dozen million zlotys we will direct funds to research teams working on the latest technologies in the field of molecular biology,” Morawiecki emphasized.

RNA technology offers hope for therapeutic solutions, incl. in the prevention and treatment of Covid-19. The ABM plans to announce a competition for the development of innovative therapeutic solutions using this technology in May 2021.

The main goal of the competition is to accelerate the implementation of innovative RNA-based therapies and make them available to patients in our country. As part of the projects selected in the competition, a universal drug platform based on RNA will be developed, which will enable the development of new-generation medicinal products used in various indications, with particular emphasis on the current needs of the pandemic based on the technology of Polish researchers.

The development of products based on nucleic acids is currently one of the most promising trends in modern biotechnology, and it is no accident that it is called the medical technology of the future. RNA is already used to activate the immune system, e.g. in anti-cancer vaccines. However, mRNA has gained a special interest in connection with the use, among others, for the production of vaccines against Covid-19.

(WBJ)